Loading patent…
AssigneeDaewoo Pharmaceutical Ind. Co., Ltd.
InventorsYoung-Hoon Ji, Dong-Hee Kim, Jae-Seon Kang, Chun-Gyu Kim, Sung-Uk Chung, Sung-Woo Hwang, Kyung-Ran Kang
Estimating the term…
The present invention relates to an anti-inflammatory use of macrolactin compounds such as macrolactin A, 7-O-malonyl macrolactin A and 7-O-succinyl macrolactin A, which are produced from a novel Bacillus strain of Bacillus polyfermenticus KJS-2 (KCCM10769P). The macrolactin compounds provided by the present invention were confirmed to greatly suppress the expression and formation of inducible nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2) which are proteins related to the formation of inflammatory mediators, and to accordingly inhibit the formation of nitric oxide (NO) and of prostaglandin E2 (PGE2) which are the metabolites of the proteins. In addition, the macrolactin compounds provided by the present invention were confirmed to have excellent effects in inhibiting the formation of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF), which are pro-inflammatory cytokines. Therefore, the macrolactin compounds produced by the Bacillus polyfermenticus KJS-2 strain according to the present invention can provide excellent anti-inflammatory agents.
1-5. (canceled)
An anti-inflammatory composition comprising an active agent selected from the group consisting of macrolactin A, 7-O-malonyl macrolactin A, and 7-O-succinyl macrolactin A, wherein the active agent is produced from the Bacillus polyfermenticus KJS-2 (KCCM10769P) strain.
A method of producing macrolactin A, 7-O-malonyl macrolactin A, or 7-O-succinyl macrolactin A comprising, carrying out a fermentation process using Bacillus polyfermenticus KJS-2 (KCCM10769P) strain.
Dependencies are inferred from the claim text.